Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer

References

• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232.
   PubMedGoogle Scholar
• Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942;115:1192.
   PubMedGoogle Scholar
• Prostate Cancer Trialist' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000;355:1491.
   Google Scholar
• Benito M, Gomberg B, Wehrli FW, Weening RH, Zemel B, Wright AC, et al Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003;88:1497.
   Google Scholar
• Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001;91:2238.
   PubMed Web of Science ®Google Scholar
• Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003;92:690.
   PubMed Web of Science ®Google Scholar
• Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens. Calcif Tissue Int 1995; 57:97–99.
   PubMed Web of Science ®Google Scholar
• Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier, C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonist for prostate carcinoma. J Urol 1999;161:1219–1222.
   PubMed Web of Science ®Google Scholar
• Daniell HW, Dunn WR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181–186.
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Terrone C, et al Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361–2367.
   PubMed Web of Science ®Google Scholar
• Higano CS, Jiang PYZ, Miller M, Pitzel M, Jensen M. Prospective evaluation of bone mineral density in prostate cancer patients without bone metastases treated with androgen suppression therapy [abstract]. Abstracts of the Third North American symposium on skeletal complications of malignancy, April 2002, Bethesda, Maryland, USA. Oncology (Huntingt) 2003;17(4 Suppl 3):32–33.
   Google Scholar
• Higano CS, et al Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64:1182–1186.
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL, et al Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–955.
   PubMed Web of Science ®Google Scholar
• Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008.
   PubMed Web of Science ®Google Scholar
• Mittan D, Lee S, Miller E, et al Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endorinol Metab 2002;87:3656–3661.
   PubMed Web of Science ®Google Scholar
• Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 2008;179:414.
   Google Scholar
• Oefelein MG, Resnick MI. The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am 2004;31:313.
   Google Scholar
• Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005.
   PubMed Web of Science ®Google Scholar
• Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004;172:2137.
   PubMedGoogle Scholar
• Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004;171:1537.
   PubMed Web of Science ®Google Scholar
• Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, et al Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416.
   PubMed Web of Science ®Google Scholar
• Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006;176:972.
   PubMed Web of Science ®Google Scholar